Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation.
about
Androgen-induced proliferative quiescence in prostate cancer cells: the role of AS3 as its mediatorLEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasionHuman prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasterideAndrogen and retinoic acid interaction in LNCaP cells, effects on cell proliferation and expression of retinoic acid receptors and epidermal growth factor receptorAndrogen-repressed phenotype in human prostate cancer.TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancerProstate cancer prevention: review of target populations, pathological biomarkers, and chemopreventive agents.HOXB13 promotes androgen independent growth of LNCaP prostate cancer cells by the activation of E2F signaling.Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell linesBipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer.Androgen suppresses the proliferation of androgen receptor-positive castration-resistant prostate cancer cells via inhibition of Cdk2, CyclinA, and Skp2.Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cellsRaloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance.Androgen and its receptor promote Bax-mediated apoptosisDoes changing androgen receptor status during prostate cancer development impact upon cholesterol homeostasis?Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cellsAndrogens as therapy for androgen receptor-positive castration-resistant prostate cancer.Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1.Longitudinal tracking of subpopulation dynamics and molecular changes during LNCaP cell castration and identification of inhibitors that could target the PSA-/lo castration-resistant cells.Identifying environmental chemicals as agonists of the androgen receptor by using a quantitative high-throughput screening platform.Caffeic Acid phenethyl ester as a potential treatment for advanced prostate cancer targeting akt signalingCholestane-3β, 5α, 6β-triol suppresses proliferation, migration, and invasion of human prostate cancer cellsThe diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer.Experimental evidence of persistent androgen-receptor-dependency in castration-resistant prostate cancer.The liver X receptor agonist T0901317 acts as androgen receptor antagonist in human prostate cancer cells.Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer.Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo.Androgen via p21 inhibits tumor necrosis factor alpha-induced JNK activation and apoptosisc-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks.Association between Serum Testosterone and PSA Levels in Middle-Aged Healthy Men from the General Population.Glutamine Transporters Are Targets of Multiple Oncogenic Signaling Pathways in Prostate Cancer.MicroRNA expressions associated with progression of prostate cancer cells to antiandrogen therapy resistance.The other face of miR-17-92a cluster, exhibiting tumor suppressor effects in prostate cancer.Interleukin 1beta mediates the modulatory effects of monocytes on LNCaP human prostate cancer cellsEffect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells.Prostate cancer cells tolerate a narrow range of androgen receptor expression and activity.Myc-dependent purine biosynthesis affects nucleolar stress and therapy response in prostate cancer.Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function
P2860
Q24290153-2776BF29-3E5D-4D61-82BD-71C1F8F89656Q24313620-78079975-808C-4B99-904F-39A66F3082B2Q24603802-FE68148E-045E-46A0-A1AB-91777D2D40F9Q24796211-3C9BD5D5-4999-4BF4-9735-FB9B027A5E4BQ30454285-BEFC8988-B9FA-40EA-8B7A-C8E6B70864DAQ33636574-6CC8549A-AEC6-442B-BE24-BC7B08E4446AQ33847495-225203DE-C1B5-40E5-90A8-FDCD42796B4EQ33933887-54122DC1-3413-4CBA-A1D3-70CDA8783952Q33988757-64DB4849-7A86-4E53-962B-DC8505E9FF66Q34124650-FB001A44-9116-4722-99B6-B41E9BEB60F7Q34278855-64EF5D6E-6B45-46B5-9EDF-9D6E4F7A7E37Q34306116-08F3D248-7C90-4271-99C7-72F379942967Q34502268-638E149D-E5D0-4F39-80E2-DBD1B7A3FC55Q34519663-DB94FF6A-39CB-4E28-A10B-18350167835BQ34548388-617DF37C-0514-43E1-B11B-0A240973B5F2Q35070404-7C7C731E-CC11-4472-8CE5-AB52F8963CBEQ35207110-51ADAEE4-A8D1-49E4-B136-7364B110BDAFQ35434843-C10C8F41-0886-4CD6-8C01-01DE87EA8E8DQ35740051-C249AF33-D7C0-4AB8-AFD7-1783ED4623C7Q35922320-DCEB791A-A9C5-400A-8DC5-BAAE14B5EC11Q36364970-167E6DDB-C55A-42CF-9086-2EE8D12039FBQ36790229-BBB0052E-FBC7-461A-9A80-85215ADA1AA4Q36926791-C8EAC1A6-F350-4F00-9BEF-0BAD08CBF771Q37074725-5220673A-0C71-47E4-8BB0-374904DC03ACQ37139070-C34AE7EC-026D-4BC1-881C-FB1AFA1E562FQ37219788-0DA06B9D-9E80-414F-8522-09D5EA380771Q37335448-A5EAF7B5-D7D3-4D2D-88D8-E29B8B01B4D8Q37389886-C5D65782-5AC0-4666-8204-7688E35A68E4Q37431953-B1A11263-D5DD-4495-94BE-D8E3469ABF81Q38707571-8FD15C16-9F94-491B-B40F-ED9F2C07D27EQ38755381-EB2CC888-2696-4667-822D-408B73328241Q38784791-19497AD1-A38B-4968-BE52-BB0ABC821A7EQ39037653-EAD4890F-C93B-47AF-A3FE-90D7663C4B8BQ39369349-65AF35B6-7427-48FF-98C2-71B84E040723Q39710081-8D53044E-64AF-4C35-9640-A3872061D789Q39744038-83945BA0-7B93-4DB6-A602-F9EB00D5CA58Q40068223-FF359CC3-D587-4B7E-9E3E-F07254A22AB8Q41261272-995913C2-C0E5-4E13-8A65-CA5A0A9C4FC5Q41827081-E2DD1539-8B8B-4DE4-80D3-A91A465E4307Q42153519-C87A428C-2BB8-405D-9663-EA71149CBD18
P2860
Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation.
description
1994 nî lūn-bûn
@nan
1994 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի մարտին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Increased androgen receptor ac ...... ong-term androgen deprivation.
@ast
Increased androgen receptor ac ...... ong-term androgen deprivation.
@en
Increased androgen receptor ac ...... ong-term androgen deprivation.
@nl
type
label
Increased androgen receptor ac ...... ong-term androgen deprivation.
@ast
Increased androgen receptor ac ...... ong-term androgen deprivation.
@en
Increased androgen receptor ac ...... ong-term androgen deprivation.
@nl
prefLabel
Increased androgen receptor ac ...... ong-term androgen deprivation.
@ast
Increased androgen receptor ac ...... ong-term androgen deprivation.
@en
Increased androgen receptor ac ...... ong-term androgen deprivation.
@nl
P2093
P1433
P1476
Increased androgen receptor ac ...... long-term androgen deprivation
@en
P2093
P304
P407
P577
1994-03-01T00:00:00Z